Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. develops clinical-stage cancer therapies centered on PLK1 inhibition and its lead oral inhibitor onvansertib. Company news commonly covers onvansertib in RAS-mutated metastatic colorectal cancer, including the CRDF-004 Phase 2 program evaluating combinations with standard-of-care regimens such as FOLFIRI/bevacizumab and FOLFOX/bevacizumab.
Updates also include preclinical and investigator-initiated work in other oncology settings, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, HER2-low breast cancer models and chronic myelomonocytic leukemia. Corporate releases also address oncology conference presentations, key opinion leader events, executive appointments, investor conferences and Nasdaq inducement equity grants.
Summary not available.
Cardiff Oncology (Nasdaq: CRDF) entered into definitive agreements for a registered direct offering of 8,571,429 common shares with accompanying warrants to purchase up to 8,571,429 shares at a purchase price of $1.05 per share plus warrant. Certain officers and directors will separately purchase 731,707 shares and warrants at $1.435 per share plus warrant.
The warrants will have an exercise price of $1.31, become exercisable six months after issuance and following an increase in authorized common shares after stockholder approval, and will expire five and a half years from initial exercise. Closing is expected on or about July 16, 2026, with anticipated gross proceeds of approximately $10 million before fees. According to Cardiff Oncology, net proceeds are intended for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as exclusive placement agent, and the securities are issued under an effective SEC shelf registration.
Cardiff Oncology (Nasdaq: CRDF) reported positive Phase 2 results for onvansertib in first-line RAS‑mutated metastatic colorectal cancer. The 30 mg onvansertib + FOLFIRI/bevacizumab arm achieved a confirmed ORR of 72.2% vs 42.1% for standard FOLFIRI/bevacizumab, with median PFS not yet reached and a favorable safety profile. A randomized Phase 3 registrational trial of onvansertib 30 mg + FOLFIRI/bevacizumab vs standard-of-care is planned following an End‑of‑Phase 2 FDA meeting. An investor webcast is scheduled for June 3, 2026.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech focused on PLK1 inhibition in cancer, will participate in the Jefferies Global Healthcare Conference from June 2-4, 2026. Management will join a fireside chat and 1x1 investor meetings.
The fireside chat with President and CEO Mani Mohindru, PhD is scheduled for June 4, 2026, from 10:30-11:00 AM ET. A live webcast and replay will be available via the Events section of the Cardiff Oncology website.
Cardiff Oncology (Nasdaq: CRDF) will host an investor webcast on June 3, 2026 at 8:30 a.m. ET to review updated Phase 2 CRDF-004 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer.
The updated data will first be presented in an ASCO 2026 rapid oral session on June 2, 2026.
Cardiff Oncology (Nasdaq: CRDF) reported Q1 2026 results and clinical progress for onvansertib in first-line RAS-mutated metastatic colorectal cancer.
Highlights include a successful End-of-Phase 2 FDA meeting, Phase 3 dose/regimen selection, strong Phase 2 ORR and PFS data, new leadership hires, and cash runway into Q1 2027.
Cardiff Oncology (Nasdaq: CRDF) announced an inducement equity grant for its new Chief Operating Officer, Dr. Aggarwal. The Compensation Committee approved non-qualified stock options to purchase 400,000 shares outside the 2021 Omnibus Plan.
The option was granted effective April 27, 2026 at an exercise price of $1.72 per share (closing price on the grant date) and vests over four years: 25% after 12 months, then monthly over 36 months, subject to continued employment.
Cardiff Oncology (Nasdaq: CRDF) will host a key opinion leader webinar on April 30, 2026 at 11:00 a.m. ET to discuss investigator-initiated trial data showing single-agent activity of onvansertib in chronic myelomonocytic leukemia (CMML).
Registration and live webcast access are available via the company Events page; a replay will be posted after the discussion.
Cardiff Oncology (Nasdaq: CRDF) will present updated Phase 2 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) at ASCO 2026. The rapid oral presentation (Abstract #3510) is scheduled for June 2, 2026, 8:00-9:30 AM CDT.
The abstract will be publicly available May 21, 2026, and the presentation will be posted on the company’s Scientific Publications page after ASCO.
Cardiff Oncology (Nasdaq: CRDF) will present preclinical poster data at AACR 2026 showing its oral PLK1 inhibitor onvansertib potentiates trastuzumab deruxtecan (T-DXd) in HER2-low breast cancer models.
The combination produced tumor regression in nearly all mice, with complete responses up to 62%, synergistic cell‑kill in resistant lines, extended event‑free survival, and favorable tolerability. Poster available April 19, 2026; online after presentation.